Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials

被引：18

作者：

Sanyal, A. ^{[1
]}

Abdelmalek, M. F. ^{[2
]}

Diehl, A. M. ^{[2
]}

Caldwell, S. ^{[3
]}

Shiffman, M. L. ^{[4
]}

Ghalib, R. ^{[5
]}

Lawitz, E. ^{[6
]}

Rockey, D. C. ^{[7
]}

Schall, R. A. ^{[8
]}

Jia, C. ^{[8
]}

McColgan, B. J. ^{[8
]}

Myers, R. ^{[8
]}

Subramanian, G. M. ^{[8
]}

McHutchison, J. G. ^{[8
]}

Ratziu, V. ^{[9
]}

Afdhal, N. ^{[10
,11
]}

Goodman, Z. ^{[12
]}

Harrison, S. A. ^{[13
]}

Bosch, J. ^{[14
]}

机构：

[1] Virginia Commonwealth Univ, Richmond, VA 23284 USA

[2] Duke Clin Res Inst, Durham, NC USA

[3] Univ Virginia, Charlottesville, VA 22903 USA

[4] Liver Inst Virginia, Richmond, VA USA

[5] Teas Clin Res Inst, Arlington, TX USA

[6] Univ Texas Hlth Sci Ctr San Antonio, Texas Liver Inst, San Antonio, TX 78229 USA

[7] Med Univ South Carolina, Charleston, SC USA

[8] Gilead Sci, Foster City, CA USA

[9] Hop La Pitie Salpetriere, Paris, France

[10] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA

[11] Harvard Med Sch, Boston, MA USA

[12] Inova Fairfax Hosp, Falls Church, VA USA

[13] Pinnacle Clin Res, San Antonio, TX USA

[14] Univ Barcelona, Barcelona, Spain

来源：

JOURNAL OF HEPATOLOGY | 2017年 / 66卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(17)30370-7

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PS-094

引用

页码：S54 / S54

页数：1

共 50 条

[1] Efficacy and safety of simtuzumab for the treatment of primary sclerosing cholangitis: results of a phase 2b, dose-ranging, randomized, placebo-controlled trial
Muir, A.
Goodman, Z.
Levy, C.
Janssen, H.
Montano-Loza, A.
Bowlus, C.
Ding, D.
Jia, C.
McColgan, B.
Myers, R.
Subramanian, M.
McHutchison, J.
Manns, M.
Chapman, R.
Afdhal, N.
Eksteen, B.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S73 - S73
[2] The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis
Abdelmalek, Manal F.
Charles, Edgar D.
Sanyal, Arun J.
Harrison, Stephen A.
Neuschwander-Tetri, Brent A.
Goodman, Zachary
Ehman, Richard A.
Karsdal, Morten
Nakajima, Atsushi
Du, Shuyan
Tirucherai, Giridhar S.
Klinger, George H.
Mora, Johanna
Yamaguchi, Masayuki
Shevell, Diane E.
Loomba, Rohit
CONTEMPORARY CLINICAL TRIALS, 2021, 104
[3] Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
Papp, K. A.
Menter, A.
Strober, B.
Langley, R. G.
Buonanno, M.
Wolk, R.
Gupta, P.
Krishnaswami, S.
Tan, H.
Harness, J. A.
BRITISH JOURNAL OF DERMATOLOGY, 2012, 167 (03) : 668 - 677
[4] Safety of galcanezumab in patients with episodic migraine: A randomized placebo-controlled dose-ranging Phase 2b study
Oakes, Tina Marie Myers
Skljarevski, Vladimir
Zhang, Qi
Kielbasa, William
Hodsdon, Michael E.
Detke, Holland C.
Camporeale, Angelo
Saper, Joel R.
CEPHALALGIA, 2018, 38 (06) : 1015 - 1025
[5] Linzagolix for treating endometriosis-associated pain: efficacy and safety results from a randomized, placebo-controlled, multinational, phase 2b dose-ranging trial
Bestel, E.
Humberstone, A.
Lecomte, V.
Dubouloz, R.
Terrill, P.
Donnez, J.
Taylor, H.
Taylor, R.
Loumaye, E.
HUMAN REPRODUCTION, 2019, 34 : 64 - 64
[6] Phase 2 randomized, placebo-controlled, dose-ranging study to evaluate the safety and efficacy of onabotulinumtoxina for the treatment of platysma prominence
Rohrich, Rodney
Bank, David E.
Bertucci, Vince
Biesman, Brian S.
Dayan, Steven
Humphrey, Shannon
Jones, Derek
Kaufman-Janette, Joely
Muhn, Channy Y.
Rivers, Jason K.
Tong, Warren
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB171 - AB171
[7] EFFICACY AND SAFETY OF PEGBELFERMIN IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND COMPENSATED CIRRHOSIS: RESULTS FROM THE PHASE 2b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED FALCON 2 STUDY
Abdelmalek, Manal F.
Sanyal, Arun J.
Nakajima, Atsushi
Neuschwander-Tetri, Brent A.
Goodman, Zachary
Lawitz, Eric J.
Harrison, Stephen A.
Jacobson, Ira M.
Imajo, Kento
Gunn, Nadege
Marzio, Dina Halegoua-De
Akahane, Takemi
Boone, Bradly
Yamaguchi, Masayuki
Chatterjee, Arkendu
Tirucherai, Giridhar S.
Shevell, Diane E.
Du, Shuyan
Charles, Edgar D.
Loomba, Rohit
HEPATOLOGY, 2021, 74 (06) : 1396A - 1397A
[8] Iscalimab (CFZ533) in Patients with Sjogren's Disease: Week 24 Efficacy and Safety Results of a Randomized, Placebo-controlled, Phase 2b Dose-ranging Study
Fisher, Benjamin A.
Mariette, Xavier
Papas, Athena S.
Grader-Beck, Thomas
Bootsma, Hendrika
Ng, Wan-Fai
Van Daele, Paul
Finzel, Stephanie
Elgueta, Sergio
Hermann, Josef
McCoy, Sara
Bookman, Arthur
Sopala, Monika
Luo, Wen-Lin
Scheurer, Cornelia
Hueber, Wolfgang
ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3242 - 3244
[9] Safety and Efficacy of Ianalumab in Patients With Sjögren's Disease: 52-Week Results From a Randomized, Placebo-Controlled, Phase 2b Dose-Ranging Study
Doerner, Thomas
Bowman, Simon J.
Fox, Robert
Mariette, Xavier
Papas, Athena
Grader-Beck, Thomas
Fisher, Benjamin A.
Barcelos, Filipe
De Vita, Salvatore
Schulze-Koops, Hendrik
Moots, Robert J.
Junge, Guido
Woznicki, Janice
Sopala, Monika
Avrameas, Alexandre
Luo, Wen-Lin
Hueber, Wolfgang
ARTHRITIS & RHEUMATOLOGY, 2025,
[10] EFFICACY AND SAFETY OF PEGBELFERMIN IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 3 FIBROSIS: RESULTS FROM THE PHASE 2b, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED FALCON 1 STUDY
Loomba, Rohit
Sanyal, Arun J.
Nakajima, Atsushi
Neuschwander-Tetri, Brent A.
Goodman, Zachary
Harrison, Stephen A.
Lawitz, Eric J.
Gunn, Nadege
Imajo, Kento
Ravendhran, Natarajan
Akahane, Takemi
Boone, Bradly
Yamaguchi, Masayuki
Chatterjee, Arkendu
Tirucherai, Giridhar S.
Shevell, Diane E.
Du, Shuyan
Charles, Edgar D.
Abdelmalek, Manal F.
HEPATOLOGY, 2021, 74 (06) : 1385A - 1386A

← 1 2 3 4 5 →